Trials / Completed
CompletedNCT00095160
Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (planned)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study 1493-852A is a phase 1 study with the primary objective of determining safety and the highest tolerated dose of an experimental immune response modifier administered intravenously to patients with solid organ tumors not responsive to currently available treatments. The secondary objective of the study is to monitor the tumor response to this form of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 852A |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2004-11-02
- Last updated
- 2017-11-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00095160. Inclusion in this directory is not an endorsement.